NASDAQ · KZIA
Healthcare · Biotechnology
$8.02
Down-$0.48 (-5.65%)
Updated Nov 3, 2026, 8:03 AM
SID Score
4.5/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · KZIA
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 2, 2026
KZIA closed at $8.02 after 21 trading sessions, down 14.22% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 2, 2026 | $8.63 | $8.75 | $7.8039 | $8.02 | 156.04K |
| Oct 30, 2026 | $8.71 | $8.7144 | $7.92 | $8.50 | 230.44K |
| Oct 29, 2026 | $9.10 | $9.10 | $8.352 | $8.72 | 222.01K |
| Oct 28, 2026 | $8.27 | $8.37 | $8.06 | $8.33 | 160.83K |
| Oct 27, 2026 | $8.03 | $8.54 | $7.81 | $8.17 | 231.93K |
| Oct 26, 2026 | $8.00 | $8.1799 | $7.6036 | $7.87 | 189.22K |
| Oct 23, 2026 | $7.9813 | $8.06 | $7.475 | $7.81 | 52.68K |
| Oct 22, 2026 | $8.04 | $8.36 | $7.25 | $8.07 | 128.76K |
| Oct 21, 2026 | $8.11 | $8.38 | $8.0401 | $8.18 | 166.15K |
| Oct 20, 2026 | $8.21 | $8.21 | $7.81 | $7.88 | 168.24K |
| Oct 19, 2026 | $7.42 | $7.93 | $7.31 | $7.85 | 245.15K |
| Oct 16, 2026 | $7.44 | $7.79 | $7.15 | $7.25 | 276.31K |
| Oct 15, 2026 | $6.80 | $7.59 | $6.80 | $7.40 | 385.75K |
| Oct 14, 2026 | $7.85 | $8.31 | $6.62 | $6.79 | 825.37K |
| Oct 13, 2026 | $8.77 | $8.94 | $8.00 | $8.04 | 277.31K |
| Oct 12, 2026 | $9.05 | $9.18 | $8.72 | $8.81 | 67K |
| Oct 9, 2026 | $8.89 | $9.08 | $8.75 | $8.93 | 123.44K |
| Oct 8, 2026 | $9.25 | $9.51 | $8.71 | $8.82 | 252.6K |
| Oct 7, 2026 | $9.20 | $9.53 | $9.14 | $9.29 | 133.54K |
| Oct 6, 2026 | $9.53 | $9.65 | $9.1625 | $9.26 | 129.94K |
| Oct 5, 2026 | $9.31 | $9.54 | $9.12 | $9.35 | 240.61K |
The latest Smart Investors Daily articles mentioning KZIA.
Company
Market Activity
Research & News
KZIA research
Company profile and research snapshot.
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 30, 2026 | Needham | Buy | — |
| Oct 21, 2026 | Guggenheim | Buy | — |
| Oct 20, 2026 | Leerink Partners | Outperform | — |
| Sep 10, 2026 | BTIG | Buy | — |
| Sep 1, 2026 | BTIG | Buy | — |
No generated briefing is available yet.
Benzinga · Jan 30, 2026
Data identify nuclear PD-L1 as a previously unaddressed driver of immunotherapy resistance and metastatic progressionSYDNEY, Jan. 30, 2026 /PRNewswire/ -- Kazia Therapeutics (NASDAQ:KZIA), an oncology-focused
Benzinga · Jan 28, 2026
HC Wainwright & Co. analyst Sean Lee reiterates Kazia Therapeutics (NASDAQ:KZIA) with a Buy and maintains $18 price target.
Yahoo · Jan 27, 2026
Kazia Therapeutics (NASDAQ: KZIA), today provided a clinical update from its ongoing Phase 1b study evaluating paxalisib in combination with pembrolizumab and chemotherapy in patients with late-stage (Stage IV), metastatic triple-negative breast cancer (TNBC).
Yahoo · Jan 8, 2026
Kazia Therapeutics (NASDAQ: KZIA) today announced that its Chief Executive Officer, John Friend, MD, will be in San Francisco next week to participate in meetings during the annual J.P. Morgan Healthcare Conference week (JPM Week).
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning KZIA.
